Are you over 18 and want to see adult content?
More Annotations
A complete backup of dougieswargamingblog.blogspot.com
Are you over 18 and want to see adult content?
A complete backup of growingfamilybenefits.com
Are you over 18 and want to see adult content?
A complete backup of notariosyregistradores.com
Are you over 18 and want to see adult content?
A complete backup of cosmos-hotel.com.tw
Are you over 18 and want to see adult content?
A complete backup of suomienglantisanakirja.fi
Are you over 18 and want to see adult content?
A complete backup of lesbicanarias.es
Are you over 18 and want to see adult content?
A complete backup of amamirantarou.tumblr.com
Are you over 18 and want to see adult content?
A complete backup of todonatacion.net
Are you over 18 and want to see adult content?
Favourite Annotations
Simplify Your Mobile, Modular & Storage Needs | 360MobileOffice
Are you over 18 and want to see adult content?
Business Plan Writers - Business Plan Consultant | Pro Business Plans
Are you over 18 and want to see adult content?
Первый доктор | Медицинский справочник
Are you over 18 and want to see adult content?
Mathematical Modelling of Natural Phenomena
Are you over 18 and want to see adult content?
Teaching with Children's Books - Bringing your favorite books to life one activity at a time.
Are you over 18 and want to see adult content?
Text
PRODUCT PORTFOLIO
Marketed Therapies. Below is a list of our company's marketed products. This information is intended only for U.S. residents. For product information for other countries, please visitALZHEIMER'S DISEASE
Alzheimer’s disease is a progressive neurological illness that impairs thinking and independence of millions of people worldwide. 1 Today, more than 5 million Americans and more than 40 million people worldwide are living with Alzheimer’s disease and related dementias, and these numbers are growing rapidly. This disease destroys not only quality of life but also quantity – it is the 3 rdCAREERS - BIOGEN
Internships & Co-ops. Throughout the year, we welcome students at all levels and from all backgrounds to bring their passion, persistence, creativity, collaboration and focus to Biogen to work alongside employees as colleagues, tackling meaningful projects and shaping their career aspirations. Learn more. Q1 2021 EARNINGS CALL WEBCAST Biogen Reports First Quarter 2021 Results. 813.7 KB. Q1 2021 Biogen Earnings Presentation. 2.3 MB. ELEMENTS OF OUR CULTURE Elements of Our Culture. Much like the periodic table of elements documents the building blocks of the universe around us, the Biogen Elements give shape to our company’s culture. They include fundamentals like a pioneering spirit, strong ethics, personal accountability, inclusivity, agility, and an COMMUNITY AND FOUNDATION The Biogen Foundation supports access to science education and to essential human services for children and their families in the communities in which Biogen facilities are located. The Foundation is committed to sparking a passion for science and discovery, supporting effective science education initiatives and strengthening efforts to make science education and science careers accessible to UPDATE ON TOFERSEN CLINICAL PROGRAM Tofersen is an investigational molecule for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). A mutation in the SOD1 gene is believed to be a genetic driver of disease in approximately two percent of all ALS patients. The safety and efficacy of tofersen is still being investigated in a Phase 3 placebo-controlled clinicalstudy.
EMERGE AND ENGAGE TOPLINE RESULTS: TWO PHASE 3 STUDIES TO 1 April 2020 1Biogen, Cambridge, MA, USA EMERGE and ENGAGE Topline Results: Two Phase 3 Studies to Evaluate Aducanumab in Patients With Early Alzheimer’s Disease AAT-AD/PD, Vienna, AustriaNETSCALER AAA
SECURITY INFORMATION. Whenever you download a file over the Internet, there is always a risk that it will contain a security threat (a virus or a program that can damage your computer and the BIOGEN | HOMEPIPELINEALZHEIMER'S DISEASECONTACT USINVESTOR RELATIONSCAREERSMULTIPLE SCLEROSIS (MS) Biogen is committed to the power of diversity – in our organization and among our patients and customers. Diversity is an essential asset of complementary strengths and perspectives from which all benefit, and which must unite us, not divide us. Learn more about our commitment. Where Science Meets Humanity. YouTube.PRODUCT PORTFOLIO
Marketed Therapies. Below is a list of our company's marketed products. This information is intended only for U.S. residents. For product information for other countries, please visitALZHEIMER'S DISEASE
Alzheimer’s disease is a progressive neurological illness that impairs thinking and independence of millions of people worldwide. 1 Today, more than 5 million Americans and more than 40 million people worldwide are living with Alzheimer’s disease and related dementias, and these numbers are growing rapidly. This disease destroys not only quality of life but also quantity – it is the 3 rdCAREERS - BIOGEN
Internships & Co-ops. Throughout the year, we welcome students at all levels and from all backgrounds to bring their passion, persistence, creativity, collaboration and focus to Biogen to work alongside employees as colleagues, tackling meaningful projects and shaping their career aspirations. Learn more. Q1 2021 EARNINGS CALL WEBCAST Biogen Reports First Quarter 2021 Results. 813.7 KB. Q1 2021 Biogen Earnings Presentation. 2.3 MB. ELEMENTS OF OUR CULTURE Elements of Our Culture. Much like the periodic table of elements documents the building blocks of the universe around us, the Biogen Elements give shape to our company’s culture. They include fundamentals like a pioneering spirit, strong ethics, personal accountability, inclusivity, agility, and an COMMUNITY AND FOUNDATION The Biogen Foundation supports access to science education and to essential human services for children and their families in the communities in which Biogen facilities are located. The Foundation is committed to sparking a passion for science and discovery, supporting effective science education initiatives and strengthening efforts to make science education and science careers accessible to UPDATE ON TOFERSEN CLINICAL PROGRAM Tofersen is an investigational molecule for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). A mutation in the SOD1 gene is believed to be a genetic driver of disease in approximately two percent of all ALS patients. The safety and efficacy of tofersen is still being investigated in a Phase 3 placebo-controlled clinicalstudy.
EMERGE AND ENGAGE TOPLINE RESULTS: TWO PHASE 3 STUDIES TO 1 April 2020 1Biogen, Cambridge, MA, USA EMERGE and ENGAGE Topline Results: Two Phase 3 Studies to Evaluate Aducanumab in Patients With Early Alzheimer’s Disease AAT-AD/PD, Vienna, AustriaNETSCALER AAA
SECURITY INFORMATION. Whenever you download a file over the Internet, there is always a risk that it will contain a security threat (a virus or a program that can damage your computer and the BIOGEN ANNOUNCES INVESTOR DAY ON SEPTEMBER 21, 2021 CAMBRIDGE, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today that it will hold an Investor Day focused on its broad pipeline across neuroscience and related therapeutic adjacencies. The event will be webcast live on September 21, 2021 at 10:00 a.m. ET. Further details will follow.PRODUCT PORTFOLIO
Marketed Therapies. Below is a list of our company's marketed products. This information is intended only for U.S. residents. For product information for other countries, please visitBIOGEN | NEWSROOM
Biogen Announces Webcast of Annual Meeting of Stockholders. Cambridge, Mass. – Biogen Inc. (Nasdaq: BIIB) announced today that the webcast of the Company's 2021 Annual Meeting of Stockholders will be held on Wednesday, June 2, 2021 at 9:00 a.m. Eastern Time. A live audio webcast of the meeting will be available on the Investor Relations BIOGEN | INVESTOR RELATIONS One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today, Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinalmuscular
BIOGEN ANNOUNCES TOPLINE RESULTS FROM PHASE 2/3 GENE CAMBRIDGE, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced topline results from the Phase 2/3 XIRIUS study of cotoretigene toliparvovec (BIIB112), a gene therapy being investigated as a one-time therapy for patients with X-linked retinitis pigmentosa (XLRP). XLRP is a rare, inherited retinal diseasethat is
2020 ESG DATA TABLE
2020 ESG Data Table. ERM Certification and Verification Services, Inc. (ERM CVS) assured the 2020 data for a number of indicators, including GHG emissions and select environmental and social indicators. See the ERM CVS Assurance Statement for full details of the assurance scope, assurance standards used, work undertaken and conclusions, andALZHEIMERS THERAPY
At Biogen, our mission is clear: we are pioneers in neuroscience. Since our founding in 1978 as one of the world’s first global biotechnology companies, Biogen has led innovative scientific research with the goal over the last decade to defeat devastating neurologicaldiseases.
BIOGEN TO LAUNCH PIONEERING STUDY TO DEVELOP DIGITAL Biogen and Bio-Thera Announce Positive Results From Phase 3 Study of BAT1806, a Proposed Biosimilar Referencing Actemra® (Tocilizumab) The comparative study met its primary endpoints and showed equivalent efficacy and comparable safety profile in patients with moderate-to-severe rheumatoid arthritis CAMBRIDGE, Mass. and GUANGZHOU, China, June 01, 2021 (GLOBE UPDATE ON TOFERSEN CLINICAL PROGRAM Tofersen is an investigational molecule for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). A mutation in the SOD1 gene is believed to be a genetic driver of disease in approximately two percent of all ALS patients. The safety and efficacy of tofersen is still being investigated in a Phase 3 placebo-controlled clinicalstudy.
SERVER LOGIN
Log in. Username:: Forgot Username: Password:assword: BIOGEN | HOMEPIPELINEALZHEIMER'S DISEASECONTACT USINVESTOR RELATIONSCAREERSMULTIPLE SCLEROSIS (MS) Biogen is committed to the power of diversity – in our organization and among our patients and customers. Diversity is an essential asset of complementary strengths and perspectives from which all benefit, and which must unite us, not divide us. Learn more about our commitment. Where Science Meets Humanity. YouTube.CAREERS - BIOGEN
Internships & Co-ops. Throughout the year, we welcome students at all levels and from all backgrounds to bring their passion, persistence, creativity, collaboration and focus to Biogen to work alongside employees as colleagues, tackling meaningful projects and shaping their career aspirations. Learn more. ELEMENTS OF OUR CULTURE Elements of Our Culture. Much like the periodic table of elements documents the building blocks of the universe around us, the Biogen Elements give shape to our company’s culture. They include fundamentals like a pioneering spirit, strong ethics, personal accountability, inclusivity, agility, and an BIOGEN | NEWSROOMBIIB LATEST NEWS Biogen Announces Webcast of Annual Meeting of Stockholders. Cambridge, Mass. – Biogen Inc. (Nasdaq: BIIB) announced today that the webcast of the Company's 2021 Annual Meeting of Stockholders will be held on Wednesday, June 2, 2021 at 9:00 a.m. Eastern Time. A live audio webcast of the meeting will be available on the Investor RelationsBIOGEN | HOME
Contact a member of the Medical Research team. Biogen Medical Research, Worldwide Medical: 225 Binney Street. Cambridge, MA 02142. MedicalResearch@biogen.com. Date Q1 2021 EARNINGS CALL WEBCAST Supporting Materials. Biogen Reports First Quarter 2021 Results. 813.7 KB. Q1 2021 Biogen Earnings Presentation. 2.3 MB. Tools. Print Page. Stockholder Communications. E-mail Alerts. COMMUNITY AND FOUNDATION The Biogen Foundation supports access to science education and to essential human services for children and their families in the communities in which Biogen facilities are located. The Foundation is committed to sparking a passion for science and discovery, supporting effective science education initiatives and strengthening efforts to make science education and science careers accessible to BIOGEN | HOMEBIOGEN GRANT APPLICATION Tel.: 1-617-914-1299 Tel. (toll free): 1-866-840-1146 Monday - Friday from 8am - 4pm EST grantsandgiving@biogen.com www.biogengrantsandgivingportal.comALZHEIMER'S DISEASE
Alzheimer’s disease is a progressive neurological illness that impairs thinking and independence of millions of people worldwide. 1 Today, more than 5 million Americans and more than 40 million people worldwide are living with Alzheimer’s disease and related dementias, and these numbers are growing rapidly. This disease destroys not only quality of life but also quantity – it is the 3 rdNETSCALER AAA
SECURITY INFORMATION. Whenever you download a file over the Internet, there is always a risk that it will contain a security threat (a virus or a program that can damage your computer and the BIOGEN | HOMEPIPELINEALZHEIMER'S DISEASECONTACT USINVESTOR RELATIONSCAREERSMULTIPLE SCLEROSIS (MS) Biogen is committed to the power of diversity – in our organization and among our patients and customers. Diversity is an essential asset of complementary strengths and perspectives from which all benefit, and which must unite us, not divide us. Learn more about our commitment. Where Science Meets Humanity. YouTube.CAREERS - BIOGEN
Internships & Co-ops. Throughout the year, we welcome students at all levels and from all backgrounds to bring their passion, persistence, creativity, collaboration and focus to Biogen to work alongside employees as colleagues, tackling meaningful projects and shaping their career aspirations. Learn more. ELEMENTS OF OUR CULTURE Elements of Our Culture. Much like the periodic table of elements documents the building blocks of the universe around us, the Biogen Elements give shape to our company’s culture. They include fundamentals like a pioneering spirit, strong ethics, personal accountability, inclusivity, agility, and an BIOGEN | NEWSROOMBIIB LATEST NEWS Biogen Announces Webcast of Annual Meeting of Stockholders. Cambridge, Mass. – Biogen Inc. (Nasdaq: BIIB) announced today that the webcast of the Company's 2021 Annual Meeting of Stockholders will be held on Wednesday, June 2, 2021 at 9:00 a.m. Eastern Time. A live audio webcast of the meeting will be available on the Investor RelationsBIOGEN | HOME
Contact a member of the Medical Research team. Biogen Medical Research, Worldwide Medical: 225 Binney Street. Cambridge, MA 02142. MedicalResearch@biogen.com. Date Q1 2021 EARNINGS CALL WEBCAST Supporting Materials. Biogen Reports First Quarter 2021 Results. 813.7 KB. Q1 2021 Biogen Earnings Presentation. 2.3 MB. Tools. Print Page. Stockholder Communications. E-mail Alerts. COMMUNITY AND FOUNDATION The Biogen Foundation supports access to science education and to essential human services for children and their families in the communities in which Biogen facilities are located. The Foundation is committed to sparking a passion for science and discovery, supporting effective science education initiatives and strengthening efforts to make science education and science careers accessible to BIOGEN | HOMEBIOGEN GRANT APPLICATION Tel.: 1-617-914-1299 Tel. (toll free): 1-866-840-1146 Monday - Friday from 8am - 4pm EST grantsandgiving@biogen.com www.biogengrantsandgivingportal.comALZHEIMER'S DISEASE
Alzheimer’s disease is a progressive neurological illness that impairs thinking and independence of millions of people worldwide. 1 Today, more than 5 million Americans and more than 40 million people worldwide are living with Alzheimer’s disease and related dementias, and these numbers are growing rapidly. This disease destroys not only quality of life but also quantity – it is the 3 rdNETSCALER AAA
SECURITY INFORMATION. Whenever you download a file over the Internet, there is always a risk that it will contain a security threat (a virus or a program that can damage your computer and thePRODUCT PORTFOLIO
Marketed Therapies. Below is a list of our company's marketed products. This information is intended only for U.S. residents. For product information for other countries, please visitBIOGEN | HOME
Contact a member of the Medical Research team. Biogen Medical Research, Worldwide Medical: 225 Binney Street. Cambridge, MA 02142. MedicalResearch@biogen.com. Date BIOGEN | INVESTOR RELATIONS One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today, Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinalmuscular
ACCESS PROGRAMS
Early Access Programs, or EAPs, may provide investigational therapies to a limited number of people who have a serious or life-threatening disease for which there are no appropriate treatment options, clinical trials or they are not eligible or able to participate in a clinical trial. If an EAP program is in place, specific eligibility criteriaBIOGEN MIT
The Biogen-MIT Biotech in Action: Virtual Summer Lab is a summer program co-created by the Biogen Community lab and the Lemelson-MIT Program at the Massachusetts Institute of Technology! Together, we have created a state-of-the-art, virtual program to allow us to continue to inspire and empower a new generation of young scientists.ALZHEIMER'S DISEASE
Alzheimer’s disease is a progressive neurological illness that impairs thinking and independence of millions of people worldwide. 1 Today, more than 5 million Americans and more than 40 million people worldwide are living with Alzheimer’s disease and related dementias, and these numbers are growing rapidly. This disease destroys not only quality of life but also quantity – it is the 3 rdALZHEIMERS THERAPY
At Biogen, our mission is clear: we are pioneers in neuroscience. Since our founding in 1978 as one of the world’s first global biotechnology companies, Biogen has led innovative scientific research with the goal over the last decade to defeat devastating neurologicaldiseases.
MULTIPLE SCLEROSIS
Multiple Sclerosis (MS) MS causes the body’s immune system to attack myelin, a protective sheath covering nerve fibers. Damage to myelin “short circuits” communication between the brain, spinal cord and other areas of the body, severely impairing such neurologicalfunctions as
A LETTER FROM BIOGEN’S CEO ON ADUHELM Today, on behalf of my Biogen colleagues, I am incredibly humbled to share that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for ADUHELM™ (aducanumab-avwa), the first-ever therapy to address a defining pathology of Alzheimer’s disease—amyloid beta plaque.SERVER LOGIN
Log in. Username:: Forgot Username: Password:assword: BIOGEN | HOMEPIPELINEALZHEIMER'S DISEASECONTACT USINVESTOR RELATIONSCAREERSMULTIPLE SCLEROSIS (MS) Biogen is committed to the power of diversity – in our organization and among our patients and customers. Diversity is an essential asset of complementary strengths and perspectives from which all benefit, and which must unite us, not divide us. Learn more about our commitment. Where Science Meets Humanity. YouTube.CAREERS - BIOGEN
Internships & Co-ops. Throughout the year, we welcome students at all levels and from all backgrounds to bring their passion, persistence, creativity, collaboration and focus to Biogen to work alongside employees as colleagues, tackling meaningful projects and shaping their career aspirations. Learn more. ELEMENTS OF OUR CULTURE Elements of Our Culture. Much like the periodic table of elements documents the building blocks of the universe around us, the Biogen Elements give shape to our company’s culture. They include fundamentals like a pioneering spirit, strong ethics, personal accountability, inclusivity, agility, and an BIOGEN | NEWSROOMBIIB LATEST NEWS Biogen Announces Webcast of Annual Meeting of Stockholders. Cambridge, Mass. – Biogen Inc. (Nasdaq: BIIB) announced today that the webcast of the Company's 2021 Annual Meeting of Stockholders will be held on Wednesday, June 2, 2021 at 9:00 a.m. Eastern Time. A live audio webcast of the meeting will be available on the Investor RelationsBIOGEN | HOME
Contact a member of the Medical Research team. Biogen Medical Research, Worldwide Medical: 225 Binney Street. Cambridge, MA 02142. MedicalResearch@biogen.com. Date Q1 2021 EARNINGS CALL WEBCAST Supporting Materials. Biogen Reports First Quarter 2021 Results. 813.7 KB. Q1 2021 Biogen Earnings Presentation. 2.3 MB. Tools. Print Page. Stockholder Communications. E-mail Alerts. COMMUNITY AND FOUNDATION The Biogen Foundation supports access to science education and to essential human services for children and their families in the communities in which Biogen facilities are located. The Foundation is committed to sparking a passion for science and discovery, supporting effective science education initiatives and strengthening efforts to make science education and science careers accessible to BIOGEN | HOMEBIOGEN GRANT APPLICATION Tel.: 1-617-914-1299 Tel. (toll free): 1-866-840-1146 Monday - Friday from 8am - 4pm EST grantsandgiving@biogen.com www.biogengrantsandgivingportal.comALZHEIMER'S DISEASE
Alzheimer’s disease is a progressive neurological illness that impairs thinking and independence of millions of people worldwide. 1 Today, more than 5 million Americans and more than 40 million people worldwide are living with Alzheimer’s disease and related dementias, and these numbers are growing rapidly. This disease destroys not only quality of life but also quantity – it is the 3 rdNETSCALER AAA
SECURITY INFORMATION. Whenever you download a file over the Internet, there is always a risk that it will contain a security threat (a virus or a program that can damage your computer and the BIOGEN | HOMEPIPELINEALZHEIMER'S DISEASECONTACT USINVESTOR RELATIONSCAREERSMULTIPLE SCLEROSIS (MS) Biogen is committed to the power of diversity – in our organization and among our patients and customers. Diversity is an essential asset of complementary strengths and perspectives from which all benefit, and which must unite us, not divide us. Learn more about our commitment. Where Science Meets Humanity. YouTube.CAREERS - BIOGEN
Internships & Co-ops. Throughout the year, we welcome students at all levels and from all backgrounds to bring their passion, persistence, creativity, collaboration and focus to Biogen to work alongside employees as colleagues, tackling meaningful projects and shaping their career aspirations. Learn more. ELEMENTS OF OUR CULTURE Elements of Our Culture. Much like the periodic table of elements documents the building blocks of the universe around us, the Biogen Elements give shape to our company’s culture. They include fundamentals like a pioneering spirit, strong ethics, personal accountability, inclusivity, agility, and an BIOGEN | NEWSROOMBIIB LATEST NEWS Biogen Announces Webcast of Annual Meeting of Stockholders. Cambridge, Mass. – Biogen Inc. (Nasdaq: BIIB) announced today that the webcast of the Company's 2021 Annual Meeting of Stockholders will be held on Wednesday, June 2, 2021 at 9:00 a.m. Eastern Time. A live audio webcast of the meeting will be available on the Investor RelationsBIOGEN | HOME
Contact a member of the Medical Research team. Biogen Medical Research, Worldwide Medical: 225 Binney Street. Cambridge, MA 02142. MedicalResearch@biogen.com. Date Q1 2021 EARNINGS CALL WEBCAST Supporting Materials. Biogen Reports First Quarter 2021 Results. 813.7 KB. Q1 2021 Biogen Earnings Presentation. 2.3 MB. Tools. Print Page. Stockholder Communications. E-mail Alerts. COMMUNITY AND FOUNDATION The Biogen Foundation supports access to science education and to essential human services for children and their families in the communities in which Biogen facilities are located. The Foundation is committed to sparking a passion for science and discovery, supporting effective science education initiatives and strengthening efforts to make science education and science careers accessible to BIOGEN | HOMEBIOGEN GRANT APPLICATION Tel.: 1-617-914-1299 Tel. (toll free): 1-866-840-1146 Monday - Friday from 8am - 4pm EST grantsandgiving@biogen.com www.biogengrantsandgivingportal.comALZHEIMER'S DISEASE
Alzheimer’s disease is a progressive neurological illness that impairs thinking and independence of millions of people worldwide. 1 Today, more than 5 million Americans and more than 40 million people worldwide are living with Alzheimer’s disease and related dementias, and these numbers are growing rapidly. This disease destroys not only quality of life but also quantity – it is the 3 rdNETSCALER AAA
SECURITY INFORMATION. Whenever you download a file over the Internet, there is always a risk that it will contain a security threat (a virus or a program that can damage your computer and thePRODUCT PORTFOLIO
Marketed Therapies. Below is a list of our company's marketed products. This information is intended only for U.S. residents. For product information for other countries, please visitBIOGEN | HOME
Contact a member of the Medical Research team. Biogen Medical Research, Worldwide Medical: 225 Binney Street. Cambridge, MA 02142. MedicalResearch@biogen.com. Date BIOGEN | INVESTOR RELATIONS One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today, Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinalmuscular
ACCESS PROGRAMS
Early Access Programs, or EAPs, may provide investigational therapies to a limited number of people who have a serious or life-threatening disease for which there are no appropriate treatment options, clinical trials or they are not eligible or able to participate in a clinical trial. If an EAP program is in place, specific eligibility criteriaBIOGEN MIT
The Biogen-MIT Biotech in Action: Virtual Summer Lab is a summer program co-created by the Biogen Community lab and the Lemelson-MIT Program at the Massachusetts Institute of Technology! Together, we have created a state-of-the-art, virtual program to allow us to continue to inspire and empower a new generation of young scientists.ALZHEIMER'S DISEASE
Alzheimer’s disease is a progressive neurological illness that impairs thinking and independence of millions of people worldwide. 1 Today, more than 5 million Americans and more than 40 million people worldwide are living with Alzheimer’s disease and related dementias, and these numbers are growing rapidly. This disease destroys not only quality of life but also quantity – it is the 3 rdALZHEIMERS THERAPY
At Biogen, our mission is clear: we are pioneers in neuroscience. Since our founding in 1978 as one of the world’s first global biotechnology companies, Biogen has led innovative scientific research with the goal over the last decade to defeat devastating neurologicaldiseases.
UPDATE ON TOFERSEN CLINICAL PROGRAM Tofersen is an investigational molecule for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). A mutation in the SOD1 gene is believed to be a genetic driver of disease in approximately two percent of all ALS patients. The safety and efficacy of tofersen is still being investigated in a Phase 3 placebo-controlled clinicalstudy.
MULTIPLE SCLEROSIS
Multiple Sclerosis (MS) MS causes the body’s immune system to attack myelin, a protective sheath covering nerve fibers. Damage to myelin “short circuits” communication between the brain, spinal cord and other areas of the body, severely impairing such neurologicalfunctions as
SERVER LOGIN
Log in. Username:: Forgot Username: Password:assword: tags on every page of your site. -->* Who We Are
* Focus on Neuroscience * Corporate Responsibility * 2019 Year in Review*
__
* Our Stories
* News Releases
* Investors
* Careers
* Medical Professionals* Global Websites
Follow us:
*
*
*
*
__Menu
Who We Are
At Biogen, our mission is clear: we are pioneers in neuroscience. Since our founding in 1978 as one of the world’s first global biotechnology companies, Biogen has led innovative scientific research with the goal over the last decade to defeat devastating neurologicaldiseases.
* ABOUT BIOGEN
* Company Overview
* History
* Elements of Our Culture * Diversity & Inclusion* Contact Us
* LEADERSHIP
* Corporate Governance * Board of Directors * Executive Leadership * PHARMACEUTICAL OPERATIONS & TECHNOLOGY * Pharmaceutical Operations & Technology* Working with Us
* GUIDING PRINCIPLES * Transparency Reporting * Code of Business Conduct * Biogen Anti-Slavery and Human Trafficking Statement * Pricing Principles__Menu
Focus on Neuroscience We believe that no other disease area holds as much need or as much promise for medical breakthroughs as neuroscience. Our focus on neuroscience, our deep scientific expertise and our courage to take risks make us leaders in the research and development of medicines to transform neuroscience to benefit society.* DISEASE AREAS
* Multiple Sclerosis * Spinal Muscular Atrophy * Alzheimer's Disease* Biosimilars
* Biosimilars
* PRODUCTS
* Product Portfolio
* SCIENCE FOR THE FUTURE * Scientific Expertise* Pipeline
* PATIENT RESOURCES
* Clinical Trials
* Access Programs
* Financial Assistance* Patient Safety
__Menu
Corporate Responsibility Biogen contributes to the communities where we live. We are committed to our employees, diversity and inclusion, and environmentalsustainability.
* CORPORATE RESPONSIBILITY* Overview
* 2019 Year in Review* Access Programs
* Environment
* Diversity & Inclusion* Corporate Giving
* COMMUNITY AND FOUNDATION* Overview
* STAR Initiative
* SPARK Video Contest* Community Lab
* Community Lab Summer Program__Menu
2019 Year in Review
Learn about our commitment to corporate responsibility, such as the many ways Biogen transformed patients' lives, empowered our employees and served our communities in 2019. * Where Science Meets Humanity * 2019 Year in Review * Purpose and Performance * Pioneering Science* Our People
* Patients
* Community and Environment* Reporting
__Menu
Our Stories
* OUR STORIES
* Our Stories
* News Releases
__Menu
Latest News
* NEWS
* News Releases
__Menu
Investors
* INVESTORS
* Investors Overview* News Releases
* Events
* Presentations
* Stock Information
* FAQs
* RESOURCES
* Executive Leadership * Board of Directors* Pipeline
__Menu
Careers
We work together to bring life-changing therapies to patients every day. Start here to find the fulfilling career opportunity that’s right for you. Please be advised that all legitimate correspondence from a Biogen employee will come from "@biogen.com" or “@brassring.com” email accounts. EXPLORE OPPORTUNITIES__
__
* All
* Administrative
* Commercial
* Corporate Affairs
* Engineering
* Environmental Health & Safety * Facilities & Infrastructure * Finance & Accounting* Human Resources
* Information Technology* Interns & Co-ops
* Legal & Compliance* Manufacturing
* Market Access
* Medical Affairs
* Patient Services
* Procurement
* Quality
* Regulatory
* Research & Development* Sales & Marketing
* Security
* Supply Chain Operations * Technical Development__
* All
* Argentina-Buenos Aires * Australia-North Ryde* Austria-Vienna
* Brazil-Sao Paulo
* Canada-Mississauga* China-Beijing
* China-Shanghai
* Denmark-Copenhagen* Field Locations
* Finland-Espoo
* France-Nanterre Cedex* Germany-Ismaning
* Hungary-Budapest
* Italy-Milano
* Japan-Tokyo
* Korea-Seoul
* Mexico-Mexico City Services * Netherlands-Badhoevedorp* Norway-Oslo
* Poland-Warsaw
* Slovenia-Ljubljana * Sweden-Upplands Vasby * Switzerland-Solothurn * Switzerland-Zug Affiliate * Switzerland-Zug Headquarters* Taiwan-Taipei
* UK-Maidenhead
* US-DC-Washington DC* US-MA-Cambridge
* US-MA-Weston
* US-Research Triangle Park-5000 Davis Drive * US-Research Triangle Park-900 Davis Drive*
* CAREERS
* Careers Overview
* FAQs
* Job Categories
* Talent Community
* Working at Biogen
* Diversity & Inclusion * Elements of Our Culture * Authorized Recruitment Activities * Student & post-graduate opportunities * Internships & Co-ops * PharmD Fellowships* PhD Fellowship
* Postdoc Program
__Menu
Medical Professionals* Resources
* For Medical Professionals * Transparency Reporting * Medical Information* Corporate Giving
__Menu
Global Websites
* Global site
* International HQ
* Argentina
* Australia
* Austria
* Belgium
* Brazil
* Canada
* China
* Colombia
* Czech Republic
* Denmark
* Finland
* France
* Germany
* Hungary
* Ireland
* Italy
* Japan
* Korea
* Mexico
* The Netherlands
* New Zealand
* Norway
* Poland
* Portugal
* Slovak Republic
* Slovenia
* Spain
* Sweden
* Switzerland
* Taiwan
* United Kingdom
PIONEERS IN NEUROSCIENCE BIOGEN COVID-19 INFORMATION CENTER Thank you to the many front-line workers and organizations working tirelessly to help in these difficult days. Please find updates on Biogen’s response to COVID-19 here.Learn more
__
*
* Clinical Trials
* Pipeline
* Investors
* Careers
* News
* 2019 Year in Review__
4/27/20 4:06 PM EDT
Biogen Prices $3.0 Billion of Senior Unsecured NotesView all news
2019 Year in Review
Science that transforms patient lives. Science that seeks to solve societal problems. Science that acts with purpose. Science that is inspired by the diversity and passion of our people. Discover where science meets humanity at Biogen in our 2019 Year in Review.
More
Our focus
We believe that no other disease area holds as much need or as much promise for medical breakthroughs as neuroscience.View full pipeline
> “Our goal is to deliver innovative therapies for patients and > invest in the areas of highest return to deliver long-term value to > our stockholders.”>
> Michel Vounatsos, CEO> More
__ __
Find disease information* Select
* Multiple Sclerosis (MS) * Spinal Muscular Atrophy (SMA) * Alzheimer's Disease* Biosimilars
* Pipeline of investigational therapies* Product Portfolio
__
Our People
Meet Tennille.
Tennille works in our Patient Services group in Research Triangle Parkin North Carolina.
More
Our People
Meet Jeffrey.
Hear from Jeffrey on the work of Diversity & Inclusion at Biogen.More
Our People
Meet Bob.
Bob and his colleagues work diligently to ensure our employees aresafe.
More __ __
REGARDING ADUCANUMAB Biogen shared Phase 3 top-line data on our investigational therapy for early Alzheimer’s disease at the 12th Clinical Trials on Alzheimer's Disease (CTAD) conference. Watch the presentation.
For investor inquiries related to this announcement, please contact Biogen Investor Relations at IR@biogen.com. On October 22, 2019, Biogen announced that, after consulting with the U.S. Food and Drug Administration (FDA), Biogen plans to pursue regulatory approval for aducanumab, an investigational treatment for early Alzheimer’s disease.Learn more .
Follow us on social media* YouTube
×
IMPORTANT NOTICE:
You are now leaving Biogen’s corporate website. We encourage you to read and evaluate terms of use, privacy, security and other similar policies of the destination site as they may differ from Biogen’s standards._Third Party Sites_
Biogen assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site's endorsement of Biogen or this website. Thank you for visiting our site.Cancel Continue
* Investors
* Careers
* News Releases
* Our Stories
* Contact Us
Follow us:
*
*
*
*
* Privacy Policy
* Terms & Conditions * Forward-Looking Statement * Community Guidelines* © 2020 Biogen
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0